ID   NR1H3_RAT               Reviewed;         445 AA.
AC   Q62685;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-OCT-2024, entry version 166.
DE   RecName: Full=Oxysterols receptor LXR-alpha;
DE   AltName: Full=Liver X receptor alpha;
DE   AltName: Full=Nuclear receptor subfamily 1 group H member 3;
DE   AltName: Full=RLD-1;
GN   Name=Nr1h3; Synonyms=Lxra;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=7935418; DOI=10.1128/mcb.14.10.7025-7035.1994;
RA   Apfel R.H., Benbrook D., Lernhardt E., Ortiz M.A., Salbert G., Pfahl M.;
RT   "A novel orphan receptor specific for a subset of thyroid hormone-
RT   responsive elements and its interaction with the retinoid/thyroid hormone
RT   receptor subfamily.";
RL   Mol. Cell. Biol. 14:7025-7035(1994).
RN   [2]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-191, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Nuclear receptor that exhibits a ligand-dependent
CC       transcriptional activation activity. Interaction with retinoic acid
CC       receptor (RXR) shifts RXR from its role as a silent DNA-binding partner
CC       to an active ligand-binding subunit in mediating retinoid responses
CC       through target genes defined by LXRES. LXRES are DR4-type response
CC       elements characterized by direct repeats of two similar hexanuclotide
CC       half-sites spaced by four nucleotides. Plays an important role in the
CC       regulation of cholesterol homeostasis, regulating cholesterol uptake
CC       through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8.
CC       Interplays functionally with RORA for the regulation of genes involved
CC       in liver metabolism (By similarity). Induces LPCAT3-dependent
CC       phospholipid remodeling in endoplasmic reticulum (ER) membranes of
CC       hepatocytes, driving SREBF1 processing and lipogenesis (By similarity).
CC       Via LPCAT3, triggers the incorporation of arachidonate into
CC       phosphatidylcholines of ER membranes, increasing membrane dynamics and
CC       enabling triacylglycerols transfer to nascent very low-density
CC       lipoprotein (VLDL) particles (By similarity). Via LPCAT3 also
CC       counteracts lipid-induced ER stress response and inflammation, likely
CC       by modulating SRC kinase membrane compartmentalization and limiting the
CC       synthesis of lipid inflammatory mediators (By similarity).
CC       {ECO:0000250|UniProtKB:Q13133, ECO:0000250|UniProtKB:Q9Z0Y9}.
CC   -!- SUBUNIT: Heterodimer of NR1H3 and RXR (retinoic acid receptor).
CC       Interacts with CCAR2 (via N-terminus) in a ligand-independent manner.
CC       Interacts with SIRT1 and this interaction is inhibited by CCAR2.
CC       {ECO:0000250|UniProtKB:Q13133}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:Q9Z0Y9,
CC       ECO:0000255|PROSITE-ProRule:PRU00407}. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q9Z0Y9}.
CC   -!- TISSUE SPECIFICITY: In adults it is expressed in spleen, pituitary,
CC       lung, liver, and fat. Weaker expression is observed in several other
CC       tissues.
CC   -!- PTM: Ubiquitinated by UBR5, leading to its degradation: UBR5
CC       specifically recognizes and binds ligand-bound NR1H3 when it is not
CC       associated with coactivators (NCOAs). In presence of NCOAs, the UBR5-
CC       degron is not accessible, preventing its ubiquitination and
CC       degradation. {ECO:0000250|UniProtKB:Q13133}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR1
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U11685; AAA53633.1; -; mRNA.
DR   PIR; A56043; A56043.
DR   AlphaFoldDB; Q62685; -.
DR   SMR; Q62685; -.
DR   STRING; 10116.ENSRNOP00000018154; -.
DR   ChEMBL; CHEMBL4523336; -.
DR   iPTMnet; Q62685; -.
DR   PhosphoSitePlus; Q62685; -.
DR   PaxDb; 10116-ENSRNOP00000018154; -.
DR   UCSC; RGD:61909; rat.
DR   AGR; RGD:61909; -.
DR   RGD; 61909; Nr1h3.
DR   eggNOG; KOG3575; Eukaryota.
DR   InParanoid; Q62685; -.
DR   PhylomeDB; Q62685; -.
DR   Reactome; R-RNO-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-RNO-4090294; SUMOylation of intracellular receptors.
DR   Reactome; R-RNO-8866427; VLDLR internalisation and degradation.
DR   Reactome; R-RNO-9029569; NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux.
DR   Reactome; R-RNO-9623433; NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis.
DR   PRO; PR:Q62685; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0000785; C:chromatin; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005730; C:nucleolus; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0043235; C:receptor complex; ISO:RGD.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISO:RGD.
DR   GO; GO:0031490; F:chromatin DNA binding; ISO:RGD.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISO:RGD.
DR   GO; GO:0004879; F:nuclear receptor activity; ISS:UniProtKB.
DR   GO; GO:0046965; F:nuclear retinoid X receptor binding; IPI:RGD.
DR   GO; GO:0003707; F:nuclear steroid receptor activity; TAS:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:0032810; F:sterol response element binding; ISO:RGD.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISO:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0043277; P:apoptotic cell clearance; ISO:RGD.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0044255; P:cellular lipid metabolic process; ISO:RGD.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; ISO:RGD.
DR   GO; GO:0009267; P:cellular response to starvation; IEP:RGD.
DR   GO; GO:0042632; P:cholesterol homeostasis; ISS:UniProtKB.
DR   GO; GO:0048565; P:digestive tract development; IEP:RGD.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IEP:RGD.
DR   GO; GO:0055088; P:lipid homeostasis; ISO:RGD.
DR   GO; GO:0001889; P:liver development; IEP:RGD.
DR   GO; GO:0042789; P:mRNA transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0010887; P:negative regulation of cholesterol storage; ISO:RGD.
DR   GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0032369; P:negative regulation of lipid transport; ISO:RGD.
DR   GO; GO:0043031; P:negative regulation of macrophage activation; ISO:RGD.
DR   GO; GO:0090188; P:negative regulation of pancreatic juice secretion; ISO:RGD.
DR   GO; GO:0048550; P:negative regulation of pinocytosis; ISO:RGD.
DR   GO; GO:0045861; P:negative regulation of proteolysis; ISO:RGD.
DR   GO; GO:1903573; P:negative regulation of response to endoplasmic reticulum stress; ISS:UniProtKB.
DR   GO; GO:0090341; P:negative regulation of secretion of lysosomal enzymes; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0036151; P:phosphatidylcholine acyl-chain remodeling; ISS:UniProtKB.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; ISS:UniProtKB.
DR   GO; GO:0032376; P:positive regulation of cholesterol transport; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0045723; P:positive regulation of fatty acid biosynthetic process; ISO:RGD.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; ISO:RGD.
DR   GO; GO:0051247; P:positive regulation of protein metabolic process; ISO:RGD.
DR   GO; GO:0034145; P:positive regulation of toll-like receptor 4 signaling pathway; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0010867; P:positive regulation of triglyceride biosynthetic process; ISO:RGD.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0019217; P:regulation of fatty acid metabolic process; IMP:RGD.
DR   GO; GO:0070723; P:response to cholesterol; IEP:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0032570; P:response to progesterone; ISO:RGD.
DR   GO; GO:0048536; P:spleen development; IEP:RGD.
DR   GO; GO:0055092; P:sterol homeostasis; ISO:RGD.
DR   GO; GO:0048538; P:thymus development; IEP:RGD.
DR   GO; GO:0070328; P:triglyceride homeostasis; ISO:RGD.
DR   CDD; cd07160; NR_DBD_LXR; 1.
DR   CDD; cd06954; NR_LBD_LXR; 1.
DR   Gene3D; 3.30.50.10; Erythroid Transcription Factor GATA-1, subunit A; 1.
DR   Gene3D; 1.10.565.10; Retinoid X Receptor; 1.
DR   InterPro; IPR023257; Liver_X_rcpt.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR050234; Nuclear_hormone_rcpt_NR1.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   PANTHER; PTHR24082; NUCLEAR HORMONE RECEPTOR; 1.
DR   PANTHER; PTHR24082:SF259; OXYSTEROLS RECEPTOR LXR-ALPHA; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR02034; LIVERXRECPTR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 1.
DR   SUPFAM; SSF48508; Nuclear receptor ligand-binding domain; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   Activator; Cytoplasm; DNA-binding; Metal-binding; Nucleus; Phosphoprotein;
KW   Receptor; Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..445
FT                   /note="Oxysterols receptor LXR-alpha"
FT                   /id="PRO_0000053537"
FT   DOMAIN          207..445
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT   DNA_BIND        93..168
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         96..116
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         132..156
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   REGION          1..94
FT                   /note="Transactivation AF-1; required for ligand-
FT                   independent transactivation function"
FT                   /evidence="ECO:0000250|UniProtKB:Q13133"
FT   REGION          1..34
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          62..86
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          178..200
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          203..445
FT                   /note="Transactivation AF-2; required for ligand-dependent
FT                   transactivation function; mediates interaction with CCAR2"
FT                   /evidence="ECO:0000250|UniProtKB:Q13133"
FT   COMPBIAS        184..200
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         191
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
SQ   SEQUENCE   445 AA;  50555 MW;  131A84AB142AEA82 CRC64;
     MSLWLEAAVP DVSPDSATEL WKTEPQDAGD QGGNTCILRE EARMPQSTGG ALRIGLESSE
     PTALLPRAET LPEPTELRPQ KRKKGPAPKM LGNELCSVCG DKASAFHYNV LSCEGCKGFF
     RRSVIKGARY ICHSGGHCPM DTYMRRKCQE CRLRKCRHAG MREECVLSEE QIRLKKLKRQ
     EEEQAQATSV SPRVSSPPQV LPQLSPEQLG MIEKLVAAQQ QCNRRSFSDR LRVTPWPIAP
     DPQSREARQQ RFAHFTELAI VSVQEIVDFA KQLPGFLQLS REDQIALLKT SAIEVMLLET
     SRRYNPGSES ITFLKDFSYN REDFAKAGLQ VEFINPIFEF SRSMNELQLN DAEFALLIAI
     SIFSADRPNV QDQLQVERLQ HTYVEALHAY VSINHPHDRL MFPRMLMKLV SLRTLSSVHS
     EQVFALRLQD KKLPPLLSEI WDVHE
//
